Phase two clinical trial of combination oxaliplatin, irinotecan, and cetuximab for patients with locally advanced or metastatic pancreatic cancer.

被引：2
|
作者：
Abdou, Yara
Friend, Sarah Cooke
Patt, Yehuda Z.
Gan, Christine
Lee, Fa-Chyi
机构：
[1] Univ New Mexico, Ctr Comprehens Canc, Albuquerque, NM 87131 USA
[2] Univ New Mexico, Albuquerque, NM 87131 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15781
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15781
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Oxaliplatin, Irinotecan and Cetuximab in Advanced Gastric Cancer. A Multicenter Phase II Trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT)
    Woell, Ewald
    Greil, Richard
    Eisterer, Wolfgang
    Bechter, Oliver
    Fridrik, Michael A.
    Gruenberger, Birgit
    Zabernigg, August
    Mayrbaeurl, Beate
    Russ, Gudrun
    Dlaska, Margit
    Obrist, Peter
    Thaler, Josef
    ANTICANCER RESEARCH, 2011, 31 (12) : 4439 - 4443
  • [22] A phase I trial of fixed-dose-rate (FDR) gemcitabine and irinotecan combination in patients with advanced pancreatic and biliary cancer.
    Sun, W
    Theobald, ME
    Hershock, D
    Haller, DG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 341S - 341S
  • [23] A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer
    Chakravarthy, A. B.
    Berlin, J. D.
    Lockhart, A. C.
    Chan, E.
    Parikh, A.
    Kordowski, V.
    Reddy, R.
    Merchant, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S250 - S251
  • [24] Phase II trial of weekly Docetaxel/Irinotecan combination in advanced pancreatic cancer
    Burtness, Barbara
    Thomas, Laurie
    Sipples, Rebecca
    McGurk, Meghan
    Salikooti, Saritha
    Christoforou, Maryanne
    Mirto, Gayle
    Salem, Ronald
    Sosa, Julieann
    Kloss, Robert
    Rahman, Zia
    Chung, Gina
    Lacy, Jill
    Murren, John R.
    CANCER JOURNAL, 2007, 13 (04): : 257 - 262
  • [25] A randomized phase I/II study of everolimus, irinotecan, and cetuximab versus capecitabine and oxaliplatin in gemcitabine-resistant patients with pancreatic cancer.
    Bjerregaard, Jon Kroll
    Ladekarl, Morten
    Jensen, Helle Anita
    Vestermark, Lene Weber
    Farr, Katherina Podlekareva
    Pfeiffer, Per
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] BTH1677 in combination with cetuximab with and without irinotecan in patients with advanced metastatic colorectal cancer
    Cornelio, Gerardo H.
    Tamayo, Maria E.
    Flores, Myra L.
    Bautista, Janet B.
    Tioleco, Paulo S.
    Gargano, Michele A.
    Kurman, Michael R.
    Walsh, Richard M.
    Beliveau, Martin
    Marier, Jean-Francois
    Patchen, Myra L.
    COLORECTAL CANCER, 2016, 5 (03) : 95 - 108
  • [27] Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer
    Brodowicz, T
    Wolfram, RM
    Köstler, WJ
    Tomek, S
    Vaclavik, I
    Steger, GG
    Teleky, B
    Függer, R
    Jakesz, R
    Zielinski, CC
    ANTI-CANCER DRUGS, 2000, 11 (08) : 623 - 628
  • [28] A PROSPECTIVE PHASE II STUDY OF CETUXIMAB IN COMBINATION WITH XELOX (CAPECITABINE AND OXALIPLATIN) IN PATIENTS WITH METASTATIC AND/OR RECURRENT ADVANCED GASTRIC CANCER
    Kim, C.
    Lee, J.
    Ryu, M.
    Chang, H. M.
    Kim, T. W.
    Kang, H. J.
    Lim, H. Y.
    Park, Y. S.
    Ryoo, B.
    Kang, Y.
    ANNALS OF ONCOLOGY, 2008, 19 : 174 - 174
  • [29] A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
    Kim, Chul
    Lee, Jae-Lyun
    Ryu, Min-Hee
    Chang, Heung Moon
    Kim, Tae Won
    Lim, Ho Young
    Kang, Hye Jin
    Park, Young Suk
    Ryoo, Baek-Yeol
    Kang, Yoon-Koo
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (02) : 366 - 373
  • [30] A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
    Chul Kim
    Jae-Lyun Lee
    Min-Hee Ryu
    Heung Moon Chang
    Tae Won Kim
    Ho Young Lim
    Hye Jin Kang
    Young Suk Park
    Baek-Yeol Ryoo
    Yoon-Koo Kang
    Investigational New Drugs, 2011, 29 : 366 - 373
12345